131I-HAb18F(ab')2在肝癌病人体内的生物学分布

24例原发性中晚期肝癌 ,用 L ugol氏液封闭甲状腺和肝胶体显像后 ,行肝动脉插管 ,经导管按 0 .5、0 .75、1.0 m Ci/ kg3个计量组给予 1 31 I- HAb18F(ab') 2 。给药后分别于 10、4 8、96、192 h再进行全身 SPECT动态显像 ,观察 1 31 I- HAb18F(ab') 2 在人体内的分布。结果显示肝癌组织中 1 31 I- HAb18F(ab') 2 明显高于其它脏器 ,且随时间延长而浓聚 ,正常肝组织和其它脏器内放射性浓聚无明显升高。研究说明 1 31 I- HAb18F(ab') 2 在人体内稳定性较好 ,与肝癌细胞能发生特异性牢固结合 ,是值得进一步研究的治疗肝癌的一类新药

Biological Distribution of 131I-HAb18F(ab')2 in Patients with Hepatocellular Carcinoma

Before 131 I HAb18F(ab') 2 administration, 24 cases of mid term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging.The cases were randomly divided into 3 groups. Then 131 I HAb18F(ab') 2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48,96 and 192 hours, 131 I HAb18F(ab') 2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131 I HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131 I HAb18F(ab') 2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.